NASDAQ: ATAIAtai Life Sciences Nv Stock
$1.42-0.05 (-3.4%)
Updated Apr 21, 2025
ATAI Price
$1.42
Fair Value Price
$0.05
Market Cap
$281.60M
52 Week Low
$1.03
52 Week High
$2.57
P/E
-1.53x
P/B
2.42x
P/S
691.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$308.00k
Earnings
-$149.27M
Gross Margin
100%
Operating Margin
-47,565.26%
Profit Margin
-48,464%
Debt to Equity
0.37
Operating Cash Flow
-$82M
Beta
1.42
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATAI Overview
Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company developing various therapeutic candidates that focus on various mental health disorders including depression, substance use disorder, and anxiety. The company's pipeline includes PCN-101, RL-007, DMX-1002, GRX-917, NN-101, VLS-01, EMP-01, RLS-01, DMX-1001, and others. Formerly known as Adripa Holding B.V., Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATAI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATAI
Ranked#428 of 462
Ranked#428 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important ATAI news, forecast changes, insider trades & much more!
ATAI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATAI ($1.42) is overvalued by 2,630.42% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATAI ($1.42) is not significantly undervalued (2,630.42%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATAI due diligence checks available for Premium users.
Valuation
ATAI fair value
Fair Value of ATAI stock based on Discounted Cash Flow (DCF)
Price
$1.42
Fair Value
$0.05
Overvalued by
2,630.42%
ATAI ($1.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATAI ($1.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.53x
Industry
-184.27x
Market
27.14x
ATAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.42x
Industry
4.04x
ATAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATAI's financial health
Profit margin
Revenue
-$5.0k
Net Income
-$39.0M
Profit Margin
779,160%
ATAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$159.4M
Liabilities
$42.8M
Debt to equity
0.37
ATAI's short-term assets ($80.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATAI's short-term assets ($80.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATAI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.3M
Investing
$6.6M
Financing
$154.0k
ATAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATAI vs Biotech Stocks
Atai Life Sciences Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.